A biotech early stage investment firm headquartered in Asia invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.
The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.
The firm does not have any specific requirements for companies and their management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based Evergreen Fund Backed by a Family Office Invests in Novel Therapeutics, Medical Devices, and Healthcare Services
24 Mar- Comments Leave a Comment
- Categories Hot Mandates
Popular Topics
Top Posts
- Hot Investor Mandate: Family Office-Backed Financial Services Firm Actively Seeks New Investment Opportunities With Strong Interests in Therapeutics & Diagnostics
- National Institute on Aging Launches Startup Challenge
- Drug Development: What Does It Cost, and Who Has The Capital?
- Come for the Pitch, Stay for the Relationship
- Family Matters in Fundraising
- First Loss Capital - What, Why & How?
- VIVA Biotech, Shanghai, China based CRO will be the Innovation Challenge Gold Sponsor for RESI
- Apply for the Digital RESI Innovation Challenge
- Crafting the Tale to Tell with Terra Bioworks
- Hot Investor Mandate: Corporate VC of Large, Global Corporation With a Thriving Healthcare Business Interested in Therapeutics, Digital Therapeutics, Medical Devices, and More
Recent Posts
- Digital Fatigue and the Future of Partnering
- The Global Entrepreneurial Classroom
- Crafting the Perfect Message
- Hot Investor Mandate: Family Office-Backed Financial Services Firm Actively Seeks New Investment Opportunities With Strong Interests in Therapeutics & Diagnostics
- Hot Investor Mandate: USA Fund of Large Asia-Based VC Firm Invests Up to $10M With Broad Interests in All Life Science Companies Based in North America and Europe
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
LSN Twitter
- Applications for @NIHAging startup challenge, The Healthy Aging Start-Up Challenge and Bootcamp to Foster Diversity… twitter.com/i/web/status/1… 2 days ago
- Digital RESI June is proud to feature service providers with tools to help the #earlystage #entrepreneur succeed in… twitter.com/i/web/status/1… 3 days ago
- Redefining Early Stage Investments (RESI), June 7-9 partnering opens TODAY! It’s not too late to book meetings with… twitter.com/i/web/status/1… 6 days ago
- Congratulations Innovator’s Pitch Challenge finalists! Applications are still open for Digital RESI, June 7-9 and d… twitter.com/i/web/status/1… 1 week ago
- FREE bootcamp: Preparing to Pitch at RESI. Hear pro tips to sharpen your #pitch TOMORROW at 11AM EDT:… twitter.com/i/web/status/1… 1 week ago
- LAST DAY to SAVE! Register for Digital #RESI, June 7-9 to SAVE $200. Meet 400+ #investors and strategic partners. S… twitter.com/i/web/status/1… 2 weeks ago
Leave a Reply